Medivir AB (publ) (LON: 0GP7)

Market Cap	23.81M
Revenue (ttm)	517.37K
Net Income (ttm)	-8.60M
Shares Out	n/a
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	540,000
Average Volume	3,717
Open	2.910
Previous Close	2.870
Day's Range	2.910 - 2.910
52-Week Range	2.910 - 7.380
Beta	0.33
RSI	25.93
Earnings Date	Feb 18, 2025

About Medivir AB

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for th...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1987
• Employees: 10
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GP7

Financial Performance

In 2023, Medivir AB's revenue was 7.63 million, an increase of 73.16% compared to the previous year's 4.41 million. Losses were -89.32 million, 0.63% more than in 2022.

Financial numbers in SEK